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Background. Renal osteodystrophy (ROD) is still one of the
major long-term complications in end-stage renal disease leading
to considerable morbidity. Despite some progress in understand-
ing the pathogenesis of secondary hyperparathyroidism (sHPT)
during recent years, prevention and treatment of ROD is still
suboptimal, requiring surgical parathyroidectomy in 6 to 10% of
all patients on dialysis after 10 years. In addition, the spectrum of
bone lesions has changed, with non-aluminum-related adynamic
bone disease (ABD) found in up to 43% of peritoneal dialysis
(PD) patients.
Methods. Current recommendations concerning prevention of
ROD in PD based on the literature and personal recent data were
reviewed. The focus is on (i) the importance of early prophylactic
intervention to prevent parathyroid gland hyperplasia, (ii) the
pathogenesis of ABD, and (iii) the role of metabolic acidosis in
ROD.
Results. There is ample evidence that sHPT starts early during
the course of renal failure and results from both hypersecretion of
PTH by parathyroid cells and glandular hyperplasia. As shown by
experimental and clinical studies, established parathyroid cell
hyperplasia is hardly reversible by pharmacological means, and
therefore prevention of parathyroid cell proliferation needs to
start early. Recent data from randomized trials document the
efficacy and safety of low dose active vitamin D (0.125 to 0.25
mg/day) and/or an oral calcium substitute to prevent progression
of sHPT in patients with mild to moderate renal failure. Since
little is known about the pathogenesis, natural course and clinical
impact of ABD in PD, specific therapeutic concepts have not yet
been generated. Diabetes and advanced age are established risk
factors, whereas the role of calcium and vitamin D overtreatment
or the type of dialysis (PD vs. HD) are still controversial.
Currently no evidence for different functional behavior of the
parathyroids in ABD and sHPT has been found. The role of
circulating or local factors such as cytokines, growth factors or the
presence of advanced glycation end-product (AGE)-modified
matrix proteins for the pathogenesis of either type of ROD
deserves further investigation. Avoiding oversuppression of para-
thyroid glands and the use of low calcium dialysate may help
prevent ABD. There is growing evidence that a correction of
metabolic acidosis will influence ROD by both direct effects on
the bone and on parathyroid cell function. New dialysate compo-
sition for CAPD with a high HCO3 concentration will allow
normalization of acid-base metabolism in PD patients. Their
effects on ROD under long term conditions remain to be deter-
mined.
Conclusion. Therapeutic efforts should aim to prevent the
development of parathyroid gland hyperplasia and sHPT early
during the course of renal failure, and should include the use of
low dose vitamin D therapy and oral calcium substitution as well
as correction of metabolic acidosis. Concerning ABD, more
information is needed regarding the causes and consequences of
this type of bone lesion to develop a more specific therapy.
Secondary hyperparathyroidism (sHPT) is still one of the
major complications of chronic renal failure, and is associ-
ated with an increasing morbidity over time. The surgical
parathyroidectomy rate is 38 per 1000 patient years after 10
years of dialysis [1]. Despite considerable progress in our
understanding of the pathogenesis of renal osteodystrophy
during the recent years [2], the therapeutic armamentarium
is still insufficient or frequently not adequately used to
prevent its development or progression [1, 3]. Major play-
ers in the pathogenic process are a decreased synthesis of
biologically active vitamin D3, hyperphosphatemia and the
skeletal resistance to parathyroid hormone (PTH), all of
which lead to or maintain hypocalcemia and hyperparathy-
roidism [2, 4]. Important cofactors like the deficiency of
receptors for vitamin D, parathyroid hormone and calcium
in parathyroid glands and bones, biologic resistance to
active vitamin D and disturbances of the acid-base balance
in uremia have now been identified to contribute substan-
tially to the pathogenesis of sHPT and osteitis fibrosa [2].
The opposite end to osteitis fibrosa in the histological
spectrum of renal osteodystrophy is represented by “ady-
namic bone disease” (ABD). Primarily found related to
aluminum deposition in bones, ABD is now recognized
with an increasing frequency as the predominant type of
lesion in a considerable number of patients who were never
exposed to aluminum, especially in the peritoneal dialysis
population [5]. While there is still debate about whether
ABD is actually a disease of the bone, the accompanying
disturbances of calcium and phosphate metabolism un-
doubtedly predispose patients to serious extraosseous com-
plications such as accelerated vascular, soft tissue and
periarticular calcifications [6, 7].
The purpose of this review is to discuss strategies for the
prevention of renal osteodystrophy and bone loss in chronic
renal failure, with a special emphasis on peritoneal dialysis.
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Due to space limitations I will concentrate on three topics:
(1) the importance of early intervention to prevent para-
thyroid gland hyperplasia, (2) the “enigma” of non-alumi-
num related ABD, and (3) new aspects concerning the
impact of metabolic acidosis and its correction on renal
osteodystrophy in peritoneal dialysis.
PREVENTION OF PARATHYROID GLAND
HYPERPLASIA
Disturbances of parathyroid hormone secretion by cal-
cium are among the important factors leading to secondary
hyperparathyroidism. As is evident from both experimental
and clinical data, the increased secretion of parathyroid
hormone results from an increased synthesis and secretion
of PTH per cell as well as an increased number of PTH
producing cells [2]. While both processes might be patho-
genetically closely related, a number of recent studies
elegantly confirmed what was suggested in early reports [8,
9]: the overwhelming importance of glandular hyperplasia
for the disturbed response of the parathyroids to calcium in
sHPT. Goodman et al studied the calcium regulated PTH
release in 26 chronic peritoneal dialysis patients with
different degrees of sHPT [10]. Performing dynamic tests
of parathyroid function, they were unable to demonstrate a
difference in the “set point” for calcium between patients
with mild or severe sHPT. In addition, the sensitivity of the
parathyroid glands to calcium was not different to that
found in healthy controls. Comparable observations were
reported by Indridason et al in hemodialysis patients with
normocalcemic sHPT [11]. In contrast to patients with
primary hyperparathyroidism or familial benign hypocalci-
uric hypercalcemia, which are disorders with a known
defect of calcium sensing, parathyroid glands of patients
with sHPT showed a normal calcium sensing. However,
there was a significant correlation between the natural
logarithm of parathyroid gland size (as assessed by ultra-
sonography), and the minimum PTH concentration under
calcium infusion (% of baseline) and the slope of the
calcium-PTH curve. The authors conclude that, at least in
normocalcemic sHPT, calcium non-suppressible PTH se-
cretion is determined by the size of the gland rather than by
a defect of calcium sensing.
Although these reports strongly support the impact of
glandular hyperplasia in the pathogenic process of sHPT,
they do not necessarily exclude that differences in the set
point for calcium might also be involved [2, 10, 11]. Indeed,
in the study by Goodman et al the set point was highest in
those two patients with the most severe sHPT who had to
be parathyroidectomized [10]. Other authors described set
point abnormalities especially in those hypercalcemic hy-
perparathyroid dialysis patients with the most advanced
forms of sHPT (“tertiary” hyperparathyroidism), and with
serum iPTH levels often exceeding 1000 pg/ml [12, 13]. It
has been hypothesized that prolonged stimulation of para-
thyroid glands may trigger the transformation of parathy-
roid cells and result in a monoclonal, nodular type of
glandular hyperplasia, as it is frequently found in the
parathyroid tissue of these patients. In vitro studies con-
firmed that parathyroid cells from those areas have a
reduced sensitivity to calcium [14].
From these studies it follows that besides suppression of
PTH hypersecretion, therapeutic efforts aiming to prevent
parathyroid gland hyperplasia are of particular importance.
In experimental uremia in the rat, Szabo et al demonstrated
that early intervention with 1,25-(OH)2 vitamin D3 prevents
parathyroid hyperplasia, as measured by 3H-thymidine
incorporation and glandular weight compared to solvent
treated controls. In contrast, when treatment was delayed
for 21 days a regression of established glandular hyperpla-
sia was not achieved by 1,25-(OH)2 vitamin D3, despite a
reduction in DNA-synthesis comparable to the early inter-
vention group [15]. What is the situation in human beings?
In a prospective trial of high dose oral versus intravenous
calcitriol pulse treatment in chronic hemodialysis patients
with advanced stages of sHPT, Quarles and coworkers
failed to achieve sustained serum PTH reduction regardless
of the mode of treatment in almost 40% of the patients. In
addition, they were unable to document any regression of
parathyroid gland size over a period of 36 weeks [16].
Similarly, Fukagawa et al found a correlation of the para-
thyroid gland size prior to calcitriol oral bolus therapy and
the long-term success of this treatment in chronic dialysis
patients. Only in patients with no or only minimally en-
larged glands, as visualized by high resolution sonography,
could a reduction in gland size and a long lasting suppres-
sion of plasma intact PTH (iPTH) be achieved. In those
with already established glandular hyperplasia, especially
with a glandular volume exceeding a threshold of 0.5 cm3,
calcitriol treatment was unable to reduce gland size and
control plasma iPTH over longer periods of time [17].
From experimental work it is still controversial whether
calcitriol can induce apoptosis in parathyroid glands, the
major pathway to induce reduction of parathyroid hyper-
cellularity in vivo [18, 19]. As demonstrated recently in a
well performed study by Ittel et al in parathyroid glands of
patients after kidney transplantation, no apoptosis was
demonstrable even after 24 months of intensive high-dose
calcitriol bolus therapy. All patients had to be parathyroid-
ectomized for recurrent hyperparathyroidism and hypercal-
cemia, showing extensive areas of the nodular type of
hyperplasia [20].
A variety of factors has been identified to contribute to
the progressive resistance of the parathyroid gland to
calcium and vitamin D in secondary hyperparathyroidism.
As has already been pointed out, with increasing gland size
and prolonged stimulation of the parathyroids more and
more areas of nodular hyperplasia are found within the
glands. These nodules are characterized by a reduced
expression of both the vitamin D and the calcium sensing
receptor [21, 22]. Cells from these areas show an alteration
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in the “set point” for calcium in vitro [14]. In addition,
monoclonal neoplastic growth has been observed in para-
thyroid glands from patients with sHPT in both areas of
nodular and diffuse hyperplasia [23]. Refractoriness to
vitamin D may further result from alteration of vitamin D
binding to its specific receptor and of the hormone receptor
complex to vitamin D receptor (VDR)-binding domains in
the DNA [24]. Finally, there is now ample evidence from in
vivo and in vitro studies that hyperphosphatemia stimulates
PTH secretion independent from changes in calcium and
calcitriol. However, whether phosphate directly promotes
parathyroid cell growth is still a matter of debate [25].
These studies demonstrate that established parathyroid
hyperplasia might not be reversed by currently available
therapeutic means.
IS THERE EVIDENCE THAT EARLY INTERVENTION
IS ABLE TO PREVENT PARATHYROID CELL
PROLIFERATION?
Two more recent trials confirmed what has been sug-
gested by early studies by Coen, Mazzaferros and Bonucci
[26], Nordal and Dahl [27], and Baker, Abrams and Roe
[28]. Given the high incidence of sHPT and abnormal bone
histology early in the course of renal insufficiency [29], both
studies examined the effect of an early vitamin D treatment
for prophylaxis of sHPT in patients with mild to moderate
renal failure [creatine clearance (CCr) 15 to 50 ml/min,
serum creatinine (SCr) 1.4 to 6.5 mg/dl, respectively]. In the
study by Hamdy et al, 76 patients were enrolled in a
double-blind randomized prospective protocol [30]. Pa-
tients in the study group received 0.25 mg calcitriol/day over
a period of 24 months compared to a control group
receiving placebo. Biochemical, radiological and histologi-
cal markers of renal osteodystrophy were assessed. After 24
months there was a significant improvement of bone his-
tology with normalization of the histological findings in
42% of patients receiving calcitriol, whereas bone histology
worsened in the majority of patients receiving placebo.
Furthermore, the administration of calcitriol did not result
in a more rapid decline of renal function, as hypercalcemic
episodes were uncommon and adynamic lesions did not
occur more often in the calcitriol treated group than in
controls. Ku¨ster and coworkers used even lower doses of
calcitriol (0.125 mg/day) in a randomized, placebo con-
trolled trial in 45 patients with mild to moderate chronic
renal failure [31]. This dose did not affect serum calcium or
phosphate levels and did not induce hypercalciuria. Al-
though bone histology was not available in this study, after
one year of treatment calcitriol prevented an increase in
intact PTH serum levels, while there was further worsening
of sHPT in the placebo group. This effect was especially
pronounced in patients with a serum creatinine at baseline
of .3 mg/dl. In conclusion, both studies show evidence that
early daily low dose therapy with active vitamin D is a safe
and efficient therapy to prevent progression of sHPT with
only little risk for worsening of renal function, hypercalce-
mia or hyperphosphatemia, and oversuppression of bone
metabolism. It should be considered especially in patients
whose iPTH levels cannot be controlled by correction of
hypocalcemia and hyperphosphatemia by administration of
calcium salts [32].
ENIGMA OF NON-ALUMINUM INDUCED
ADYNAMIC BONE DISEASE
Adynamic bone disease (ABD) is histologically charac-
terized by a low bone formation rate, a decreased number
of both osteoblasts and osteoclasts and a delayed bone
mineralization without increased osteoid formation or fi-
brosis [5]. The prevalence of this type of lesion has been
increasingly described in ESRD patients over the last few
years [33, 34]. Primarily related to aluminum deposition in
bones, there is also a substantial number of patients
presenting with this lesion who were never exposed to
aluminum and have no or only limited detectable amounts
of aluminum in bone histology [35]. According to Hercz et
al [35] and Malluche and Monier-Faugere [33] peritoneal
dialysis seems to predispose for ABD. In a recent cross
sectional multicenter study in Europe, Couttenye et al
found a prevalence of ABD of 43% in a peritoneal dialysis
population with almost no exposure to aluminum contain-
ing phosphate binders [36]. ABD has also been described
with a frequency of 12 to 48% in predialysis patients [29,
36–39]. There is still debate about the causes and natural
course as well as the meaning of this “disorder” as an actual
disease [5]. Long-term observations in patients with ABD
showed both spontaneous conversion into osteitis fibrosa or
persistence or even worsening of ABD after 12 to 24
months [37, 38, 40]. The reported increased frequency of
severe vascular calcifications in ABD patients suggests that
extraosseous complications might influence the patient’s
long-term prognosis even more than the skeletal lesions
itself [40].
Beyond aluminum deposition several risk factors have
been claimed to predispose for ABD: high calcium supple-
mentation via calcium containing phosphate binders or
high dialysate calcium concentrations, older age, diabetes
and vitamin D therapy [5, 34–39]. Looking more carefully
at a number of larger studies, only advanced age and
diabetes turned out to be common risk factors, while
vitamin D treatment and higher calcium substitution were
associated with ABD only in a minority of studies (Table 1)
[35, 36]. A common finding that might contribute to the
decrease in bone metabolism in patients with ABD is the
rather low plasma iPTH concentration [34–39]. Intact PTH
levels below 150 pg/ml are highly sensitive and specific to
detect ABD in chronic dialysis patients [41]. However, even
in patients with ABD mean plasma iPTH levels are signif-
icantly higher than in a normal control population [34–39],
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raising the question of why bone turnover remains abnor-
mally suppressed in those patients. Currently the pathogen-
esis of non-aluminum induced ABD is incompletely under-
stood. Differences in parathyroid sensitivity and response
to calcium, the absence or presence of circulating factors
such as cytokines and growth factors with regulating effects
on bone metabolism, and the presence of uremic toxins
interfering with the PTH action on renal bone cells might
be involved [42]. Goodman and coworkers studied the
parathyroid response to calcium in patients with sHPT,
adynamic bone disease and normal controls [43]. Com-
pared to healthy controls, patients with ABD and sHPT
showed a decreased responsiveness to calcium infusion.
However, the inhibitory effect of calcium on PTH release
was qualitatively and quantitatively (based on % of baseline
PTH) similar in ABD and sHPT patients. Thus, functional
differences of the parathyroid glands in response to calcium
do not seem to be responsible for the marked discrepancy
in parathyroid activity between ABD and sHPT.
Based on a close correlation of IGF-1 serum levels and
bone formation rate, Andress et al postulated an influence
of circulating IGF-1 on bone metabolism in chronic dialysis
patients [44]. However, others have reported conflicting
results [45]. IGF-1 and IGF-2 have been shown to influence
bone metabolism via both endocrine and paracrine path-
ways [46]. Recently we re-evaluated this hypothesis, assess-
ing serum IGF-1 and IGF-2 and IGFBP-2 and IGFBP-3
concentrations in 38 chronic dialysis patients (32 HD, 6
CAPD) with biochemically and histologically defined ABD
(N 5 25) or severe sHPT (N 5 13; Table 2) [47]. While
both groups were clearly separated by iPTH serum levels,
bone alkaline phosphatase activity, osteocalcin concentra-
tion and bone histology, serum IGF-1 and IGF-2 concen-
trations were not different between groups. In addition,
serum IGFBP-2 and IGFBP-3 levels did not correlate with
histological or serological findings of renal bone disease.
Thus, our data in a well characterized cohort of dialysis
patients representing opposite ends of the spectrum of
renal bone disease did not support a role for circulating
IGFs in the pathogenesis of renal bone disease. However,
these data do not exclude that alterations in the local,
bone-derived IGF system might have a potential impact on
the pathogenesis of this complication.
There is a growing body of evidence that advanced
glycation end-products (AGE) are involved in uremic tox-
icity [48]. High serum concentrations of AGE have been
found in ESRD patients compared to healthy controls [49,
50]. AGE modified molecules bind to various cells like
monocytes or endothelial cells by binding to a specific
receptor (RAGE). Binding of AGE to their receptor might
stimulate synthesis and secretion of cytokines [tumor ne-
crosis factor-a (TNF-a), interleukin-1 (IL-1)] and growth
factors [transforming growth factor-b (TGF-b), insulin-like
growth factor-1 (IGF-1)] [48]. Targets of non-enzymatic
glycation are especially molecules with a long half life, such
as matrix proteins. Based on the observation that diabetics
carry an increased risk for ABD, a lesion that might even be
found in non-uremic diabetic patients [51, 52], we asked
whether AGE modified bone matrix might participate in
the development of ABD in end-stage renal disease
(ESRD) patients. To date there is little information on the
degree of AGE-modified proteins in bone matrix and the
effects of glycated proteins on function of bone cells.
Studying IL-6 excretion in human osteoblast-like cells
(Saos) in response to non-enzymatically glycated albumin
and collagen (type I), we observed no effect of AGE on
IL-6 secretion into culture supernatants; slightly higher
values were found in cells incubated on glycated type 1
collagen compared to non-glycated collagen treated con-
trols. However, AGE-albumin and AGE-collagen signifi-
cantly inhibited the dose dependent stimulation of IL-6
secretion in response to IL-1 in Saos cells (unpublished
data; Fig. 1). While the cellular mechanisms of these effects
are still the subject of further studies, our preliminary
results suggest that the presence of AGE-modified matrix
Table 1. Risk factors for the non-aluminum related adynamic type of
renal bone disease
Reference Age
Time on
RRT/RI Diabetes
Calcium
suppl.
Vitamin
D PD
iPTHd
pg/ml
[27] 2 (2) 2 2 2 a 113 6 126
[33] 1 2 2 1 2 c , 150
[36] 1 (1)b 2 2 2 a 216 6 16
[35] 1 120
[32] 1 2 1 1 2 1 77 6 9
[30] 1 2 1 2 1
[34] 1 1 2 2 198 6 25
Abbreviations are: RRT, renal replacement therapy; RI, renal insuffi-
ciency; PD, peritoneal dialysis, suppl., supplment; PD, peritoneal dialysis;
iPTH, intact parathyroid hormone; ABD, adynamic bone disease; (1)
positive correlation; (2) no correlation.
a Only predialysis patients tested
b Positive correlation between duration of renal insufficiency and risk of
ABD
c Only peritoneal dialysis population tested
d Normal range 10–60 pg/ml
Table 2. Biochemical markers of renal osteodystrophy and serum IGF-
1 and IGF-2 levels in 38 chronic dialysis patients with non-aluminum
related adynamic bone disease (ABD) and severe secondary
hyperparathyroidism (sHPT)
ABD
(N 5 25)
sHPT
(N 5 13) P
Ca mmol/liter 2.3 6 0.18 2.5 6 0.24 NS
PO4 mmol/liter 1.79 6 0.38 2.24 6 0.56 0.01
iPTH pmol/liter 4.6 6 2.8 78.6 6 42.1 ,0.0001
bAP ug/liter 6.5 6 5.9 30.1 6 23.3 0.003
Osteocalcin ug/liter 10.86 6 5.29 34.66 6 23.03 0.004
IGF-1 ug/liter 211.8 6 112.9 191.4 6 53.3 NS
IGF-2 ug/liter 816.5 6 217.5 799.8 6 195.6 NS
Protein g/liter 68.0 69.2 NS
Data are given as mean 6 SD. Statistical analyses were performed using
the Mann-Whitney U-test.
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proteins might alter the osteoblast’s response to regulatory
hormones or cytokines. The amount and distribution of
AGE-modified matrix proteins in patients with renal bone
disease has not been reported yet and is currently being
investigated.
Despite the increasing prevalence of non-aluminum re-
lated ABD in the dialysis population and especially in
peritoneal dialysis patients, little is known about its patho-
genesis. Clearly, more information is needed about the
factors involved in the pathogenesis of this type of bone
disease and its long-term impact as a “disease” before we
can address therapeutic and prophylactic measures. Cur-
rently it is recommended that patients avoid therapeutical
oversuppression of sHPT [5]. Vitamin D should not be
given to patients with iPTH , 23 the upper limit of
normal. Lowering of dialysate calcium might be useful in
this population to stimulate parathyroid activity and allow
adequate substitution with calcium-containing phosphate
binders. The development of new, non-calcium containing
phosphate binding drugs [53] may provide a tool to ease the
task of efficient phosphate control without the risk of
hypercalcemia.
EFFECTS OF METABOLIC ACIDOSIS ON BONE
MINERAL METABOLISM
There is ample evidence that bone mineral metabolism is
altered by acute and chronic metabolic acidosis. For more
detailed information on the mechanisms involved, the
interested reader is referred to the recent in-depth review
by Bushinsky [54]. Hydrogen ions are buffered by bone
bicarbonate, exchanging sodium and potassium for protons.
Decreases in pH directly release calcium from bone. In
addition, chronic metabolic acidosis stimulates bone re-
sorption mediated by increased osteoclast activity and
inhibits osteoblast function, as demonstrated by decreased
collagen synthesis in osteoblasts. Conflicting results exist
concerning the effects of chronic metabolic acidosis on
1,25-(OH)2 vitamin D3 synthesis by 1-alpha hydroxylase
activity [55, 56]. In uremia, metabolic acidosis has been
associated with a higher frequency of osteomalacia, osteo-
fibrosis and a diminished response to vitamin D therapy
[57, 58].
DOES EVIDENCE EXIST THAT CORRECTION OF
METABOLIC ACIDOSIS IMPROVES BONE MINERAL
METABOLISM IN CHRONIC UREMIA?
In a well designed study by Lefebvre et al, 21 patients on
hemodialysis were randomly allocated to treatment with
either a conventional dialysate bicarbonate concentration
(33 mmol/liter) or dialysis with an additional supplementa-
tion of bicarbonate to elevate predialysis serum-HCO3 to
24 mmol/liter for 18 months [59]. Progression of sHPT was
documented by increased plasma PTH and bone histology
in patients treated with the conventional solution, while
there was no further progression of histological and sero-
logical findings in the patients with eubicarbonatemia.
Furthermore, in patients with a suppressed bone formation
rate at baseline, serum osteocalcin levels as a marker for
increased osteoblast activity increased in the high bicarbon-
ate group, but remained low in the control group treated
with the conventional dialysate. Metabolic acidosis may
further alter the sensitivity of the parathyroids to calcium,
as pointed out recently by Graham and coworkers [60].
Performing dynamic studies of parathyroid function the
authors could demonstrate that after optimal correction of
metabolic acidosis in hemodialysis patients the PTH/ion-
ized calcium curves were displaced downwards and to the
left, indicating an increased sensitivity of the glands to
calcium even within normal physiological limits.
In peritoneal dialysis hypobicarbonatemia and the de-
gree of metabolic acidosis seem to be less pronounced and
more stable than in hemodialysis. However, in most pa-
tients the average bicarbonate levels are lower than in the
healthy population [61]. Conventional peritoneal dialysis
solutions using lactate as buffer did not correct metabolic
acidosis completely and resulted in a constant loss of
bicarbonate into the dialysate [61]. With the development
of new dialysate solutions containing high concentrations of
HCO3 (39 mmol/liter), it seems now possible to completely
normalize metabolic acidosis in chronic peritoneal dialysis
patients [62]. Beyond normalization of acidemia, exchang-
ing lactate for bicarbonate might provide a further poten-
tial benefit for parathyroid and bone cell function. As was
shown in functional studies in red blood cells, the use of
high lactate dialysate in peritoneal dialysis is not only toxic
for cells within the peritoneal cavity, but may also affect
cellular function systemically [63], a defect that was almost
Fig. 1. Effect of advanced glycation end-products (AGE)-modified albu-
min on interleukin-6 (IL-6) secretion by human osteoblast-like cells
(Saos). Saos cells were incubated in the presence of 10% AGE-albumin
(3.5 IU/ml/mg albumin) or bovine serum albumin for 24 hours. Cultures
were stimulated with increasing concentrations of rh-IL-1b. IL-6 concen-
tration in culture supernatants was assessed by ELISA. Symbols are: (M)
bovine albumin; (u) AGE-albumin. *P , 0.05; **P , 0.001 (t-test, N 5 6).
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completely abolished by the use of bicarbonate. Whether
the use of new peritoneal dialysate solutions with high
bicarbonate concentrations will show comparable effects in
cells involved in bone and mineral metabolism, and
whether normalization of metabolic acidosis will improve
development and course of renal bone disease and prevent
bone loss in long-term peritoneal dialysis remain subjects
for future research. However, these new solutions might
offer interesting new therapeutic options for treatment and
prophylaxis of renal bone disease.
CONCLUSIONS
How can we translate what has been discussed through-
out the previous chapters into practical guidelines for the
prevention of renal bone disease in everyday clinical peri-
toneal dialysis practice?
(1) Treatment of sHPT should be started early in the
course of renal failure, that is, when CCr falls below 50
ml/min. The first line of treatment should aim to control
hypocalcemia and hyperphosphatemia by administration of
calcium-containing oral phosphate binders. If intact PTH is
not maintained within 2 to 33 the upper normal limit by
these measures, patients might benefit from a low dose
vitamin D therapy (0.125 to 0.25 mg/day) to prevent further
progression of glandular hyperplasia, particularly the de-
velopment of nodular hyperplasia. Obviously, meticulous
control of serum phosphate and calcium is mandatory, not
only before but especially during vitamin D treatment.
(2) Patients with advanced stages of sHPT may benefit
from sonographic evaluation of the gland size to guide
further treatment. Sustained control of sHPT by vitamin D
is unlikely to be achieved if parathyroid volume exceeds 0.5
cm3, equivalent to a gland weight of about 1 g. If serum
phosphate and calcium can be adequately controlled (PO4
, 1.8, Ca , 2.8 mmol/liter) high dose bolus vitamin D
therapy is a valid therapeutic option independent of the
route of administration (i.v. or orally) [16]. If iPTH does
not respond after 6 to 8 weeks of vitamin D or serum
phosphate or calcium cannot be controlled, then surgical
parathyroidectomy will be the treatment of choice.
(3) With regards to non-aluminum related ABD, infor-
mation about pathogenesis and clinical impact is too scarce
to allow specific therapeutic recommendations. However,
the use of vitamin D is not indicated in these patients. Use
of calcium containing phosphate binders might necessitate
a reduction of dialysate calcium, since hypercalcemia is a
frequent problem in ABD patients [64]. New calcium- and
aluminum-free phosphate binding agents currently in de-
velopment may become valuable alternatives in the treat-
ment of patients with ABD [53].
(4) Virtually no clinical study has assessed the effect of
correction of chronic metabolic acidosis on renal bone
disease in patients on peritoneal dialysis. However, as
might be extrapolated from studies in HD patients, nor-
malization of acidosis might improve the parathyroid re-
sponse to calcium as well as act directly on osteoblast and
osteoclast function. With the new bicarbonate-containing
peritoneal dialysis solutions are opportunities to approach
or achieve complete correction of metabolic acidosis with-
out further loss of bicarbonate into the dialysate. In addi-
tion, the potential toxic effects of lactate on bone metabo-
lism can be avoided. The clinical benefits of these solutions
for the prevention of renal bone disease, especially on the
long-term, must be assessed in future studies.
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